EP1353932A1 - Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus - Google Patents

Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus

Info

Publication number
EP1353932A1
EP1353932A1 EP02734844A EP02734844A EP1353932A1 EP 1353932 A1 EP1353932 A1 EP 1353932A1 EP 02734844 A EP02734844 A EP 02734844A EP 02734844 A EP02734844 A EP 02734844A EP 1353932 A1 EP1353932 A1 EP 1353932A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
substituted
iii
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02734844A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bernhard Keppler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niiki Pharma Inc
Original Assignee
Faustus Forschungs Cie Translational Cancer Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faustus Forschungs Cie Translational Cancer Research GmbH filed Critical Faustus Forschungs Cie Translational Cancer Research GmbH
Publication of EP1353932A1 publication Critical patent/EP1353932A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Definitions

  • compositions containing a ruthenium (III) complex and a heterocycle containing a ruthenium (III) complex and a heterocycle
  • the present invention relates to compositions comprising a ruthenium (III) complex and a heterocycle, and to their use as medicaments for the treatment of cancer.
  • Ruthenium (III) complexes with indazole and dimethyl sulfoxide were also obtained from B.K. Keppler et al., Anticancer Res., 9 (1989) 761-766, G. Mestroni et al., J.Am. Chem. Soc. 111 (1989) 7068-7071 and G. Mestroni et al., Inorg. Chem., 34 (1995) 4722-4734.
  • WO97 / 36595 discloses ruthenium (III) complexes with an alkali metal cation or with ammonium, which are good are water soluble and are also effective for the treatment of cancer.
  • these compounds have the disadvantage that they have a lower activity than ruthenium complexes according to US Pat. No. 4,843,069.
  • composition (A) which can be obtained by reacting a complex compound of the general formula (I)
  • M is an alkali metal cation or ammonium
  • B ' is a mono- or polynuclear basic heterocycle with one or more nitrogen atoms
  • X ' is a halide, pseudohalide, HC0 3 ⁇ or RCOO " , wherein R Is hydrogen or a substituted or unsubstituted Ci - C 6 alkyl or C 2 - C 6 alkenyl or a substituted or unsubstituted aryl, phosphate, sulfate and / or acetate, and s is an integer of 1 or more.
  • composition (B) obtainable by mixing a complex compound of the general formula (III)
  • B, B ' is a mono- or polynuclear basic heterocycle with one or more nitrogen atoms
  • M is an alkali metal cation or ammonium
  • X ' is a halide, pseudohalide, HC0 3 " or RCOO " wherein R is hydrogen or a substituted or unsubstituted Ci - C 6 alkyl or C 2 - C 6 alkenyl or a substituted or unsubstituted aryl, is phosphate, sulfate or acetate.
  • B and / or B 'in the formulas (I), (II) or (III) can be purine, adenine, guanine, cytosine, indazole, imidazole, pyrazole, pyridine, pyrimidine, pyridazine, pyrrole, Tetrazole, and / or triazine, which may be substituted by one or more substituents selected from the group consisting of:
  • -R1 ' is hydrogen, sodium, d-C alkyl or phenyl
  • R1' and R2 ' are hydrogen, dC 4 -alkyl, amino, or phenyl, or R1' and R2 'together represent a group - (CH 2 ) S -, where s is an even number from 4 to 8,
  • -W is a nitrogen or CR3 ', in which R3' is a hydrogen, CC 4 -alkyl, amino or phenyl, preferably hydrogen or methyl,
  • -Y is nitrogen or CR4 ', wherein R4' is hydrogen, d-d-alkyl, amino or phenyl, preferably hydrogen or methyl, and
  • R5' is hydrogen, CrC-alkyl, amino or phenyl, preferably hydrogen or methyl, the ring being attached to the basic via at least one of the substituents R1 'and R2'
  • Heterocycle B or B ' is bound.
  • At least one of the groups R3 ', R4' or R5 ' is preferably one Hydrogen.
  • the at least one substitute is preferably selected from the group consisting of chlorine, diethylamino, dimethylamino and pyrrol-1-yl-methyl.
  • B and / or B 'in the formulas (I), (II) or (III) can be 1-methylimidazole, 4-methylimidazole, 4-methylpyrazole, 1-sodium pyrazole, 1-phenyltetrazole or 5-phenyltetrazole, which may be substituted, preferably in the 4-position, by one or more substituents as defined above.
  • B and / or B 'in the formulas (I), (II) or (III) are imidazole, pyrazole, triazole or indazole, particularly preferably imidazole, triazole or indazole, even more preferably triazole or indazole, in particular indazole.
  • B 'and B can be the same, i.e. represent the same heterocycle.
  • M in the formulas (I) and (IV) is preferably lithium, sodium or potassium, in particular sodium.
  • X and / or X 'in the formulas (I), (II), (III) or (IV) are chlorine or bromine, in particular chlorine.
  • X "in composition (A) or (B) corresponds to X.
  • the molar ratio of the compound of formula (I) to the compound of formula (II) in the composition (A) according to the invention is preferably ⁇ 1, a ratio between 1: 1.1 and 1:10, in particular 1: 2 and 1: is particularly preferred 5th
  • the molar ratio of the compound of formula (III) to the compound of formula (IV) in the composition (B) according to the invention is preferred a ratio between 1: 2 and 1:30, particularly preferably 1: 5 and 1:15, in particular 1:10.
  • the compound of the formula (I) is sodium rat7S-tetrachlorobis (1 H-indazole) ruthenate (III).
  • the compound of formula (II) is preferably indazolium hydrochloride.
  • the compound of formula (III) is preferably indazolium -ra.7s- [tetrachlorobis- (indazole) ruthenate (III)].
  • the compound of formula (IV) is preferably sodium chloride.
  • composition (A) or (B) according to the invention can be in the form of an aqueous solution.
  • Composition (B) can be obtained by triturating a compound of formula (III) with a compound of formula (IV) in a mortar or in mills such as air jet or ball mills.
  • compositions (A) and / or (B) according to the invention are achieved by a pharmaceutical solved, which contains the compositions (A) and / or (B) according to the invention.
  • compositions (A) and / or (B) can also be used for the production of a medicament for the prophylaxis and / or treatment of cancer.
  • the medicaments according to the invention are administered primarily intravenously, but also intramuscularly, intraperitoneally, subcutaneously or orally. External application is also possible. Administration by intravenous injection or intravenous infusion is preferred.
  • the pharmaceutical preparations are produced by methods known per se, the composition according to the invention being used as such or, if appropriate, in combination with suitable pharmaceutical carriers. If the pharmaceutical preparations contain pharmaceutical carriers in addition to the active ingredient, the active ingredient content of these mixtures is 0.1 to 99.5, preferably 0.5 to 95% by weight of the total mixture.
  • the active substance can be used in any suitable formulation, provided that the formation or maintenance of sufficient active substance levels is ensured. This can be achieved, for example, by oral or parenteral administration in suitable doses.
  • the pharmaceutical preparation of the active ingredient is advantageously in the form of unit doses which are tailored to the desired administration.
  • a unit dose can be, for example, a tablet, a dragee, a capsule, a suppository or a measured volume of a powder, a granulate, a solution, an emulsion or a suspension.
  • Unit dose in the sense of the present invention is understood to mean a physically determined unit which contains an individual amount of contains active ingredient in combination with a pharmaceutical carrier and whose active ingredient content corresponds to a fraction or multiple of a therapeutic single dose.
  • a single dose preferably contains the amount of active ingredient which is administered in one application and which usually corresponds to a whole, a half, a third or a quarter of a daily dose. If only a fraction, such as half or a quarter, of the unit dose is required for a single therapeutic administration, the unit dose is advantageously divisible, for example in the form of a tablet with a notch.
  • the pharmaceuticals according to the invention if they are in unit doses and for applications e.g. are intended for humans, contain about 0.1 to 500 mg, preferably 10 to 200 mg and in particular 50 to 150 mg of active ingredient.
  • the active ingredient (s) are administered in a daily dose of 0.1 to 5, preferably 1 to 3 mg / kg of body weight, optionally in the form of several, preferably 1 to 3, single doses to achieve the desired results.
  • a single dose contains the active ingredient (s) in amounts of 0.1 to 5, preferably 1 to 3 mg / kg body weight. Similar doses can be used in oral treatment.
  • the therapeutic administration of the pharmaceutical preparation can take place 1 to 4 times a day at fixed or varying times, for example before meals and / or in the evening. However, it may be necessary to deviate from the doses mentioned, depending on the type, body weight and age of the individuals to be treated, the type and severity of the disease, the type of preparation and administration of the pharmaceutical preparations, and the period or Interval within which the administration takes place. In some cases it may be sufficient to make do with less than the above-mentioned amount of active ingredient, while in other cases the amount of active ingredient mentioned above must be exceeded. It may also prove expedient to administer the pharmaceutical preparations only once or at intervals of several days.
  • the determination of the required optimal dosage and type of application of the active ingredients can be done by any specialist on the basis of his specialist knowledge.
  • the pharmaceutical preparations generally consist of the composition according to the invention and non-toxic, pharmaceutically acceptable medicament carriers which are used as admixtures or diluents, for example in solid, semi-solid or liquid form or as enveloping agents, for example in the form of a capsule, a tablet cover, a sachet or another Container for the therapeutically active ingredient come into use.
  • a carrier can e.g. serve as a mediator for the absorption of medicinal products by the body, as a formulation aid, as a sweetener, as a taste corrector, as a colorant or as a preservative.
  • Tablets, dragees, hard and soft capsules e.g. come from gelatin, dispersible powders, granules, aqueous and oily suspensions, emulsions, solutions or syrups.
  • Tablets can contain inert diluents, for example calcium carbonate, calcium phosphate, sodium phosphate or lactose; Granulating and distributing agents, for example corn starch or alginates; Binding agents, for example starch, gelatin or acacia; and lubricants, for example aluminum or magnesium stearate, talc or silicone oil. They can also be provided with a coating, which can also be designed in such a way that it causes a delayed dissolution and absorption of the pharmaceutical preparation in the gastrointestinal tract, so that, for example, better tolerance, protaction or retardation is achieved.
  • Gelatin capsules can be mixed with a solid, for example calcium carbonate or kaolin, or an oily, for example olive, peanut or paraffin oil, diluent for the drug contain.
  • Aqueous suspensions can include suspending agents, e.g.
  • Dispersing and wetting agents e.g. Polyoxyethylene stearate, heptadecaethyleneoxycatanol, polyoxyethylene sorbitol monooleate or lecithin; Preservatives, e.g. Methyl or propyl hydroxybenzoates; Flavoring agents; Sweeteners, e.g. Sucrose, lactose, sodium cyclamate, dextrose, invert sugar syrup.
  • Oily suspensions can e.g. Peanut, olive, sesame, coconut or
  • Paraffin oil and thickeners such as e.g. Beeswax, hard paraffin or
  • Cetyl alcohol also sweeteners, flavoring agents and antioxidants.
  • Powders and granules dispersible in water can contain the composition according to the invention in a mixture with dispersing, wetting and suspending agents, e.g. the above, as well as with sweeteners, flavorings and colorants.
  • Emulsions can e.g. Olive, peanut, or paraffin oil in addition to emulsifiers, such as Acacia, tragacanth, phosphatides, sorbitan monooleate, polyoxyethylene sorbitan monooleate, and sweeteners and flavoring agents.
  • emulsifiers such as Acacia, tragacanth, phosphatides, sorbitan monooleate, polyoxyethylene sorbitan monooleate, and sweeteners and flavoring agents.
  • Aqueous solutions can contain preservatives, e.g. Methyl or propyl hydroxybenzoates; Thickener; Flavoring agents; Sweeteners, e.g. Contain sucrose, lactose, sodium cyclamate, dextrose, invert sugar syrup, as well as flavorings and colorings.
  • preservatives e.g. Methyl or propyl hydroxybenzoates
  • Thickener e.g. Methyl or propyl hydroxybenzoates
  • Flavoring agents e.g. Contain sucrose, lactose, sodium cyclamate, dextrose, invert sugar syrup, as well as flavorings and colorings.
  • Sterile injectable, aqueous solutions, isotonic saline solutions or other solutions are used for parenteral use of the medicinal substances.
  • Any suitable solution can be used as a solvent for infusion.
  • Preferred are water and Haemaccel ®.
  • the process according to the invention for the preparation of the composition (A) comprises the reaction of a complex compound of the formula (I) with a compound of the formula (II).
  • the reaction is preferably carried out in aqueous solution.
  • the process according to the invention for the preparation of the composition (B) comprises mixing a complex compound of the formula (III) with a compound of the formula (IV).
  • a compound of the formula (IM) is combined with a compound of the formula (IV) e.g. ground in a mortar or ball mills.
  • kit (A) which contains a container with a compound of the formula (I)
  • M is an alkali metal cation or ammonium
  • B is a single- or multi-core basic heterocycle with one or more nitrogen atoms
  • B ' is a single- or multi-core basic heterocycle with one or more nitrogen atoms
  • X ' is a halide, pseudohalide, HCO 3 ⁇ or RCOO " , wherein R is hydrogen or a substituted or unsubstituted - C 6 alkyl or C 2 - C 6 alkenyl or a substituted or unsubstituted aryl, phosphate, sulfate, acetate, and s is an integer of 1 or more.
  • X 'in kit (A) is the same as X and B is the same as B'.
  • a kit (B) which contains a container with a compound of the formula (III)
  • M is an alkali metal cation or ammonium
  • X ' is a halide, pseudohalide, HC0 3 ⁇ or RCOCT, wherein R is hydrogen or a substituted or unsubstituted Ci - C 6 alkyl or C 2 - C 6 alkenyl or a substituted or unsubstituted aryl,
  • kit (A) according to the invention is explained in more detail below.
  • the composition (A) according to the invention can be applied to the patient by providing a kit which contains an ampoule with a compound of the formula (I), preferably as the sodium salt, and separately therefrom an infusion solution which is an equimolar or else a higher one Concentration of a compound of formula (II), preferably as hydrochloride, contains.
  • an ampoule with a compound of the formula (I), preferably as the sodium salt and separately therefrom an infusion solution which is an equimolar or else a higher one Concentration of a compound of formula (II), preferably as hydrochloride, contains.
  • an ampoule with a compound of the formula (I), preferably as the sodium salt
  • an infusion solution which is an equimolar or else a higher one Concentration of a compound of formula (II), preferably as hydrochloride
  • kit (B) according to the invention is explained in more detail below.
  • the composition (B) according to the invention can be applied to the patient by providing a kit which contains an ampoule (1) with a compound of the formula (III), preferably as an indazolium salt, and separately an ampoule (2) with a compound of the formula (IV), for example sodium chloride, and a solvent for infusion.
  • an ampoule (1) with a compound of the formula (III), preferably as an indazolium salt
  • an ampoule (2) with a compound of the formula (IV), for example sodium chloride for example sodium chloride
  • the contents of the ampoule (1) are triturated with the contents of the ampoule (2), for example in a mortar, to obtain the composition (B) according to the invention.
  • the composition (B) dissolved in the solvent for infusion can then be injected into the infusion bottle and used immediately on the patient.
  • the compounds of the general formula (I) can be prepared according to the procedure described in WO 97/36595. Furthermore, the preparation of the compounds of the general formula (III) as described in J. Cancer Res. Clin. Oncol. 1992, 118 (3), pp. 195-200. The compounds of the formulas (II) and (IV) are prepared by known processes.
  • Figure 1 Formation of a composition (A) according to the invention, containing indazolium frans- [tetrachlorobis (1H-indazole) ruthenate (III)] (KP 1019) and sodium chloride, by reacting KP 1339 and indazolium hydrochloride.
  • KP 1019 indazolium frans- [tetrachlorobis (1H-indazole) ruthenate (III)]
  • KP 1019 sodium chloride
  • composition obtained according to Example 1 were carried out.
  • the composition was obtained by reacting the sodium salt KP 1339, which is more than thirty times more soluble in water than KP 1019, with indazolium hydrochloride in the infusion solution immediately before administration.
  • KP 1339 has a significantly weaker antiproliferative activity in vitro than KP 1019, further experiments were carried out to determine to what extent the stronger activity of KP 1019 can be restored by adding indazole to solutions of KP 1339.
  • the tumor-inhibiting activity of the equimolar mixture of KP 1339 and indazole was found to be identical to that of the original KP 1019 (see Figures 1 and 2), while pure KP 1339 was three to four times less effective than KP 1019. This was demonstrated on two tumor cell lines ( SW480, CH1) confirmed and reproduced four times. The lower effectiveness of KP 1339 compared to KP 1019 was confirmed in these experiments.
  • the tumor-inhibiting activity can be increased further by adding an excess of indazole.
  • a mixture of KP 1339 and indazole in a molar ratio of 1: 5 resulted in a two to five-fold increase in cytotoxicity compared to KP 1019 (see FIGS. 3 and 4).
  • a molar ratio of 1: 2 is already sufficient to exceed the effectiveness of the original KP 1019.
  • Indazole itself only exerts a cytotoxic effect in a much higher concentration (> 1 mM).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP02734844A 2001-01-26 2002-01-28 Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus Ceased EP1353932A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10103565 2001-01-26
DE10103565A DE10103565B4 (de) 2001-01-26 2001-01-26 Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
PCT/EP2002/000863 WO2002059135A1 (de) 2001-01-26 2002-01-28 Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus

Publications (1)

Publication Number Publication Date
EP1353932A1 true EP1353932A1 (de) 2003-10-22

Family

ID=7671867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02734844A Ceased EP1353932A1 (de) 2001-01-26 2002-01-28 Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus

Country Status (7)

Country Link
US (3) US7338946B2 (ja)
EP (1) EP1353932A1 (ja)
JP (2) JP2004528292A (ja)
AU (1) AU2002330518B2 (ja)
CA (1) CA2436260C (ja)
DE (1) DE10103565B4 (ja)
WO (1) WO2002059135A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2441262T3 (es) * 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
NZ595484A (en) * 2009-04-17 2014-04-30 Niiki Pharma Inc Method of treating hepatocellular carcinoma
ES2517367T3 (es) * 2009-12-11 2014-11-03 Niiki Pharma Inc. Procedimiento de tratamiento de cáncer pancreático
US8383673B2 (en) * 2010-03-19 2013-02-26 City University Of Hong Kong Nitridoosmium(VI) complexes for treatment of cancer
CN102939086B (zh) * 2010-04-19 2015-03-18 尼基制药公司 胃癌的治疗方法
CA2831208A1 (en) * 2010-04-23 2011-10-27 Niiki Pharma Inc. Method of treating prostate cancer
WO2011139867A2 (en) * 2010-04-29 2011-11-10 Niiki Pharma Inc. Method of treating brain cancer
CN103189059A (zh) * 2010-07-17 2013-07-03 尼基制药公司 治疗耐药性癌症的方法
KR101783190B1 (ko) 2010-07-18 2017-09-29 니키 파머 액퀴지션 코포레이션 2 루테늄 착체를 사용하는 병용 치료요법
AU2011323832B2 (en) * 2010-10-25 2016-06-02 Niiki Pharma Inc. Method of treating neuroendocrine tumors
JP2014500259A (ja) * 2010-11-17 2014-01-09 ニーキ ファーマ インコーポレイテッド 血液癌を処置する方法
KR20140041560A (ko) * 2011-05-17 2014-04-04 니키 파머 액퀴지션 코포레이션 2 암 치료를 위한 약제 및 방법
WO2013070988A2 (en) * 2011-11-09 2013-05-16 Niiki Pharma Inc. Method of treating osteosarcoma
US9751081B2 (en) 2014-12-01 2017-09-05 Clemson University Self-regenerating antioxidant catalysts and methods of using the same
WO2018204930A1 (en) 2017-05-05 2018-11-08 Intezyne Technologies, Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof
CN115554401A (zh) * 2022-09-24 2023-01-03 重庆医科大学 一种基于钌配合物的无载体多功能纳米颗粒的制备及其抗肿瘤应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0694471B2 (ja) * 1984-07-24 1994-11-24 アスタ・メディカ・アクチエンゲゼルシヤフト 薬理学的に認容性の錯化合物およびその製造法
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02059135A1 *

Also Published As

Publication number Publication date
US7485659B2 (en) 2009-02-03
JP2004528292A (ja) 2004-09-16
US7338946B2 (en) 2008-03-04
US7589084B2 (en) 2009-09-15
CA2436260C (en) 2009-05-05
DE10103565B4 (de) 2007-06-14
WO2002059135A1 (de) 2002-08-01
US20050032801A1 (en) 2005-02-10
CA2436260A1 (en) 2002-08-01
JP2009138005A (ja) 2009-06-25
US20070293468A1 (en) 2007-12-20
US20070293557A1 (en) 2007-12-20
DE10103565A1 (de) 2002-08-14
AU2002330518B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
EP1353932A1 (de) Zusammensetzungen, enthaltend einen ruthenium(iii)-komplex und einen heterocyclus
EP0191096B1 (de) Tumorhemmend wirkende rutheniumverbindungen
EP1984005B1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
DE10141528B4 (de) Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
EP0202673B1 (de) Cytostatisch wirksame Titanocen-Komplexe
DE2923334C2 (de) Verwendung von Cyclopentadienylmetall-Acido-Komplexen bei der Krebsbekämpfung und diese Komplexe enthaltende Arzneipräparate
EP0835112B1 (de) Arzneimittelzubereitungen enthaltend tumorhemmend wirkende ruthenium(iii)-komplexe
AT501819B1 (de) Verwendung von gallium(iii)-komplexen zur behandlung von tumorerkrankungen der leber
WO2002074304A2 (de) Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum
DE10138561B4 (de) Tumorhemmende Cerverbindungen sowie deren Verwendung
AT505367A1 (de) Tumorhemmende ruthenium und osmium- thiosemicarbazonatokomplexe
EP1377591B1 (de) Tumorhemmende galliumverbindungen
WO2002076993A1 (de) Tumorhemmende siliciumverbindungen
EP1596848A1 (de) Verwendung von 1-(2-chlorethyl)-1-nitroso-3-(2-hydroxyethyl)-urea zur behandlung von pankreaskarzinomen, weichteilsarkomen, hodentumoren, lymphomen, thymomen, wilms tumoren, nierenkarzinomen, melanomen, lungentumoren, intracerebralen metastasen, tumoren im kopf- und halsbereich, und mamma-karzinomen
DE10114106C1 (de) Tumorhemmende Siliciumverbindungen, Verfahren zu ihrer Herstellung und deren Verwendung als Arzneimittel
EP1414830A1 (de) Tumorhemmende lanthanverbindungen
AT501358A1 (de) Neue rutheniumkomplexe, verfahren zu ihrer herstellung und deren verwendung bei der bekämpfung von tumorerkrankungen
WO2006077166A1 (de) Verwendung von gallium (iii) komplexen zur behandlung von tumoren des urothelialtraktes
DE19701692A1 (de) Antineoplastisch wirkende Metallkomplexe und diese enthaltende Arzneimittel
AT503592A1 (de) Tumorhemmende galliumverbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040513

17Q First examination report despatched

Effective date: 20040513

19U Interruption of proceedings before grant

Effective date: 20080320

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20090102

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NIIKI PHARMA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100213